NCT06993675
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06993675
Title Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) (ROTATE)
Acronym ROTATE
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Noffar Bar
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.